

## Drug Monograph

Drug/Drug **Lenvima<sup>®</sup> (lenvatinib) capsules/ Oncology – Kinase**  
Class: **Inhibitors**  
Prepared for: MO HealthNet  
Prepared by: Conduent

**New Criteria**

**Revision of Existing Criteria**

### Executive Summary

**Purpose:** The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

**Dosage Forms:** Lenvima<sup>®</sup> capsules are supplied in cartons of 6 cards. Each card is a 5-day blister card and is now available as follows: A 4 mg carton with 6 cards containing five 4 mg capsules per card, and a 12 mg carton with 6 cards containing fifteen 4 mg capsules per card.

**Manufacturer:** Distributed by: Eisai Inc., Woodcliff Lake, NJ 07677

**Indications:** Lenvima<sup>®</sup> is a kinase inhibitor indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer. Also, in combination with everolimus, for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy. Also, for the first-line treatment of patients with unresectable hepatocellular carcinoma.

**Costs:** \$2,817 per carton of Lenvima<sup>®</sup> 4mg and 12mg. Maximum Allowable Cost

**Summary of Findings:** MO HealthNet Division recommends 15 Day First Fill Fiscal Edit status for this product if packaging allows.

**Status Recommendation:**  Prior Authorization (PA) Required  Open Access  
 Fiscal Edit  PDL

**Type of PA Criteria:**  Increased Risk of ADE  Preferred  
 Appropriate Indications  No PA Required

Prepared By: Jennifer Anderson PharmD  
Date: October 17, 2018